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The skin, especially the pilosebaceous unit composed of
sebaceous glands and hair follicles, can synthesize an-
drogens de novo from cholesterol or by locally convert-
ing circulating weaker androgens to more potent ones.
As in other classical steroidogenic organs, the same six
major enzyme systems are involved in cutaneous andro-
gen metabolism, namely steroid sulfatase, 3b-hydroxy-
steroid dehydrogenase, 17b-hydroxysteroid dehydrogenase,
steroid 5a-reductase, 3a-hydroxysteroid dehydrogenase,
and aromatase. Steroid sulfatase, together with P450
side chain cleavage enzyme and P450 17-hydroxylase,
was found to reside in the cytoplasm of sebocytes and
keratinocytes. Strong steroid sulfatase immunoreacti-
vity was observed in the lesional skin but not in unaf-
fected skin of acne patients. 3b-hydroxysteroid dehydro-
genase has been mainly immunolocalized to sebaceous
glands, with the type 1 being the key cutaneous isoen-
zyme. The type 2 17b-hydroxysteroid dehydrogenase
isoenzyme predominates in sebaceous glands and exhi-
bits greater reductive activity in glands from facial
areas compared with acne nonprone areas. In hair folli-
cles, 17b-hydroxysteroid dehydrogenase was identi¢ed
mainly in outer root sheath cells. The type 1 5a-reduc-
tase mainly occurs in the sebaceous glands, whereby the
type II isoenzyme seems to be localized in the hair fol-
licles. 3a-hydroxysteroid dehydrogenase converts dihy-
drotestosterone to 3a-androstanediol, and the use of
3a-androstanediol glucuronide serum level to re£ect
the hyperandrogenic state in hirsute women may be a
reliable parameter, especially for idiopathic hirsutism.
In acne patients it is still controversial if 3a-androstane-
diol glucuronide or androsterone glucuronide could
serve as suitable serum markers for measuring andro-
genicity. Aromatase, localized to sebaceous glands and
to both outer as well as inner root sheath cells of anagen
terminal hair follicles, may play a ‘‘detoxifying’’ role by
removing excess androgens. Pharmacologic develop-
ment of more potent speci¢c isoenzyme antagonists
may lead to better clinical treatment or even prevention
of androgen-dependent dermatoses. Key words: acne vul-
garis/androgen antagonists/androgenetic alopecia/androgens/
hirsutism. J Invest Dermatol 119:992 ^1007, 2002
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ex hormones, like other steroid hormones, are synthe-
sized from their major parental precursor cholesterol,
which undergoes side chain cleavage by the mitochon-
drial P450 side chain cleavage enzyme (P450scc) to
form D5-pregnenolone, releasing a C6 aldehyde. D5-
pregnenolone, the required intermediate compound in the
synthesis of all steroid hormones, can be converted intracellularly
to progesterone by the action of 3b -ol-dehydrogenase/D4,5-iso-
merase or to 17a-hydroxypregnenolone by 17a-hydroxylase. The
ring system ‘‘sterane’’ of the steroid hormones, carrying a cyclo-
pentanoperhydrophenanthrene nucleus, is a stable structure that
cannot be broken down by mammalian cells. Conversion of ac-
tive hormones to less active or inactive forms involves alteration
of ring substituents rather than the ring structure itself. Sex hor-
mones can be easily distinguished by the carbon numbers, C-19
being androgens, C-18 being estrogens, and C-21 being progeste-
noids. Androgens are derivatives of androstane and contain either
a keto group [e.g., dehydroepiandrosterone (DHEA) and andros-
tenedione] or hydroxy group [testosterone and 5a-dihydrotestos-
terone (5a-DHT)] at position 17 of the ring system.
Cholesterol synthesis in mammalian systems is regulated
by the key enzyme, 3-hydroxy-3-methylglutaryl coenzyme A
reductase, and it has been con¢rmed that this process also
occurs in the epidermis and the sebaceous glands (Menon et al,
1985; Smythe et al, 1998). Recent work demonstrated
the cutaneous expression of steroidogenic acute regulatory
protein, cytochrome P450 cholesterol side-chain cleavage
(P450scc) and cytochrome P450 17a-hydroxylase (P450c17), sug-
gesting the cutaneously derived cholesterol could be further used
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as a substrate for de novo steroid hormone synthesis in human epi-
dermis and the sebaceous gland.1,2 On the other hand, steroid
hormones inhibit the expression of 3-hydroxy-3-methylglutaryl
coenzyme A reductase in SZ95 sebocytes at the mRNA level in a
negative feedback regulation process (Zouboulis et al, 1999; 2002).
In classical ‘‘central’’ steroidogenic organs such as the gonads
and the adrenal gland, testosterone can be derived mainly
from two pathways: (i) progesterone, 17a-hydroxyprogesterone,
D4 -androstenedione, or (ii) 17a-hydroxypregnenolone, DHEA,
D5-androstenediol (Stauss and Pochi, 1969; Witt and Thorney-
croft, 1990). Alternatively, in many ‘‘peripheral’’ organs, such as
the skin, the potent tissue androgen testosterone results from
the conversion of circulating dehydroepiandrosterone sulfate
(DHEA-S), a weak but most abundant androgen in higher pri-
mates, through the serial action of steroid sulfatase, 3b-hydro-
xysteroid dehydrogenase/D54 isomerase (3b-D5-HSD), and
17b-HSD (Labrie, 1991; Fritsch et al, 2001). Testosterone can be
further ‘‘activated’’ to the physiologically most potent tissue an-
drogen 5a-DHT through the action of 5a-reductase or ‘‘inacti-
vated’’ to estradiol by aromatase (Kaufman, 1996). In contrast to
classical endocrinology depicting steroid hormone formation
and secretion from classical steroidogenic organs, such as gonads
and adrenal glands, this peripheral ‘‘on the spot’’ intracellular hor-
mone synthesis/action, now coined as ‘‘intracrinology’’, has been
shown to take place in various peripheral, hormone-target tissues
such as placenta, prostate, adipose tissue, skin, and skin appen-
dages (Fig 1) (Labrie et al, 2000a; Zouboulis, 2000a). The andro-
gen-sensitive skin appendages (sebaceous gland, hair follicle, and
sweat gland) each metabolize androgens in a characteristic
pattern; however, sweat glands and sebaceous glands account for
the vast majority of androgen metabolism in skin (Deplewski
and Rosen¢eld, 2000). In postmenopausal women, 100% of the
active sex steroids are synthesized in peripheral target tissues from
inactive steroid precursors, whereas, in adult men, approximately
50% of androgens are locally made in intracrine target tissues
(Labrie et al, 2000b). Not much is known, however, about the
extent to which (i) the de novo cutaneous androgenesis from
epidermally formed cholesterol, or (ii) the locally active conver-
sion of potent androgens from circulating DHEA contribute to
the androgens formed in the skin.
Here is a review of the recent advances in the understanding of
cutaneous androgen synthesis and metabolism, trying to correlate
the expression of di¡erent converting isoenzymes to the patho-
genesis of androgen-dependent dermatoses, such as acne vulgaris,
hirsutism, and androgenetic alopecia. The current therapeutics
and future developments based on this continuously expanding
knowledge are also discussed.
HISTORICAL REVIEW
The ¢rst recognition of the role of androgens in the pathogenesis
of cutaneous disorders probably came from Aristotle as early as
the fourth century BC, as he noticed the relation between the oc-
currence of baldness (androgenetic alopecia) and the gender state
or the sexual maturity (Montagna, 1963). It was not until 1942 as
Hamilton’s pioneering work on castrates subjected to testosterone
injections (Hamilton, 1942), which for the ¢rst time provided the
scienti¢c evidence and hence provoked further investigation on
the androgen metabolism in the skin (Takashima, 1990).
The ¢rst androgen hormone to be characterized was androster-
one isolated from the urine of adult men in 1931 (Tausk, 1968).
Testosterone was then demonstrated to be the androgen secreted
from testis in 1935. Experimental work on the androgen metabo-
lism in vitro began intensively in 1950s by applying large-scale per-
fusion (Caspi et al, 1953; Caspi and Hechter, 1954) or by incubating
animal internal organ homogenates, e.g., rat liver (Schneider and
Horstmann, 1951; Taylor, 1954; Kochakian and Stidworthy, 1954)
Figure1. Pathways of cutaneous androgen metabolism and the converting enzymes.
1Billich A, Rot A, Lam C, Schmidt JB, Schuster I: Immunohistochem-
ical localization of steroid sulfatase in acne lesions: Implications for the
contribution of dehydroepiandrosterone sulfate to the pathogenesis of acne.
Hormone Res 53:99, 2000 (Abstr.)
2Thiboutot DM, Sivarajah A, Gilliland K, Cong Z, Clawson G: The
skin as steroidogenic tissue: Enzymes and cofactors involved in the initial
steps of steroidogenesis are expressed in human skin and rat preputial sebo-
cytes. J Invest Dermatol 117:410, 2001 (Abstr.)
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with various steroids, such as cortisone, desoxycorticosterone,
progesterone, and androstenedione. Metabolites were separated
and isolated mainly by thin-layer adsorption chromatography
with paper, aluminum or silica gels as stationary phase. During
the 1950s and 1960s increasing evidence accumulated that the skin
might be one of the sites of peripheral androgen metabolism
(Wotiz et al, 1956; Stauss and Pochi, 1969). The presence of di¡er-
ent hydroxysteroid dehydrogenases, including 3a-HSD, 3b-
HSD, and 17b-HSD, was soon histochemically revealed in the
human skin (Baillie et al, 1965), especially in the sebaceous gland
(Baillie et al, 1966). Active androgen metabolism was further con-
¢rmed by incubating human skin with various (radiolabeled)
steroids (Wotiz et al, 1956; Gallegos and Berliner, 1967; Gomez
and Hsia, 1968); i.e., the activity of 17b-HSD in the skin was de-
monstrated by showing the cutaneous conversion of androstene-
dione to testosterone or 5a-androstanedione to 5a-DHT (Gomez
and Hsia, 1968). Studies on rat and human prostate showed that
5a-DHT, rather than testosterone, might be the active androgenic
hormone at the target site (Farnsworth and Brown, 1963; Bru-
chovsky and Wilson, 1968) and this conversion could also take
place in the skin (Wilson and Walker, 1969; Flamigni et al, 1971;
Bingham and Shaw, 1973). Attempts to inhibit 5a-reductase in
the skin cells were soon made (Zerhouni et al, 1979; Leshin and
Wilson, 1982). Biochemical characterization of the di¡erent an-
drogen converting enzymes, including the enzyme activity, coen-
zymes, kinetic properties, and intracellular distribution was
performed between 1970s and 1980s. Most of these data were
based on the studies on congenital adrenal hyperplasia, various
virilizing and feminizing syndromes, and hirsutism (New et al,
1981; Mauvais-Jarvis et al, 1981; James and Few, 1985). Because of
the variable stability of di¡erent enzymatic activities in broken
cell preparations and the di⁄culties in puri¢cation and stabiliza-
tion of these membrane-bound enzymes, it was not until the
1990s when the introduction of newer molecular biologic meth-
ods, such as RNA expression, cloning, and analysis that better
elucidation and comparison of the genetic structure, function,
ontogeny, and tissue-speci¢c expression of these converting
isoenzymes became feasible (Labrie, 1991; Russell and Wilson,
1994).
STEROID SULFATASE
The steroid sulfatase is a microsomal enzyme widely distributed
in human tissues that catalyzes the hydrolysis of sulfated 3-hydro-
xy steroids to the corresponding free active 3-hydroxy steroids.
Early studies in vitro and in vivo have shown that the human ster-
oid sulfatase activity appears after birth, such as in foreskin and
infantile abdominal skin (Kim and Herrmann, 1968). Major
breakthroughs in the evaluation of cutaneous expression of ster-
oid sulfatase came from the study on its role in X-linked recessive
ichthyosis, which has been shown to be associated with the de¢-
ciency of the steroid sulfatase/arylsulfatase C (Schlammadinger
et al, 1987; Herrmann, 1989; Herrmann et al, 1989). The steroid
sulfatase gene is localized to the distal short arm of the X chro-
mosome and most X-linked ichthyosis patients present large de-
letions of the steroid sulfatase gene and £anking markers, whereas
a minority show a point mutation or partial deletion of the ster-
oid sulfatase gene (Bonifas and Epstein, 1990; Basler et al, 1992;
Alperin and Shapiro, 1997; Morita et al, 1997; Sugawara et al,
2000; Valdes-Flores et al, 2001). Activity of steroid sulfatase was
also demonstrated in cultured keratinocytes (Milewich et al,
1988) in which cholesterol sulfate could inhibit sterol esteri¢ca-
tion. These data suggest a novel role for cholesterol sulfate as a
modulator of cellular lipid biosynthesis (Williams et al, 1987). In
patients with X-linked recessive ichthyosis, cholesterol sulfate ac-
cumulation rather than cholesterol de¢ciency seemed to be re-
sponsible for the barrier abnormality (Zettersten et al, 1998). On
the other hand, in the occipital scalp of normal healthy subjects as
well as in the beard, the speci¢c activity of steroid sulfatase was
signi¢cantly higher in the hair dermal papillae (DP) as com-
pared with that in the connective tissue sheaths or root sheaths
(Ho¡mann et al, 2001).
3b -D5-HSD
This enzyme catalyzes an obligatory step in the biosynthesis of
androgens, estrogens, mineralocorticoids, and glucocorticoids;
the oxidation/isomerization of 3-b-hydroxy-5-ene steroids (D5-
3b-hydroxysteroids) into the corresponding 3-keto-4-ene ster-
oids (D4 -3-ketosteroids), i.e., the transformation of DHEA into
androstenedione and androstenediol into testosterone, respec-
tively. This process could be seen as the ¢rst step to form more
potent androgens and to amplify the androgenic e¡ect. 3b-D5-
HSD is found not only in classic steroidogenic tissues (placenta,
adrenal cortex, ovary, and testis), but also in several peripheral
tissues, including skin, adipose tissue, breast, lung, endometrium,
prostate, liver, kidney, epididymis, and brain (Labrie et al, 1992).
This tissue-speci¢c manner of expression involves separate me-
chanisms of regulation. An important feature in liver and kidney
(at least of hamster, mouse, rabbit, and rat) is the sexual di-
morphic nature of 3b-D5-HSD. Two types of human 3b-D5-
HSD cDNA clones have been characterized; the corresponding
genes are located in chromosome 1p13.1, containing four exons
and three introns with a total length of 7.7^7.8 kbp, and encoding
proteins of 371 and 372 amino acids, respectively, which share
93.5% homology and both prefer NADþ as cofactors (Pelletier
et al, 1992; Labrie et al, 1995; Simard et al, 1996). Human type 1
3b-HSD is the almost exclusive mRNA species expressed in the
skin, mammary gland, and placenta (syncytial trophoblast),
whereas the type 2 isoform is almost exclusively expressed in the
adrenal cortex and the gonads.
Early studies demonstrated 3b -D5-HSD enzyme activity in
¢broblasts (Gallegos and Berliner, 1967), and that the sebaceous
gland possessed the highest activity in the human skin (Itami
and Takayasu, 1982; Simpton et al, 1983), which was further con-
¢rmed by the immunohistochemical localization of 3b-D5-HSD
speci¢cally in sebaceous glands (Dumont et al, 1992; Sawaya and
Penneys, 1992). In cultured skin cells, 3b-D5-HSD mRNA was
only detected in normal and immortalized sebocytes (SZ95), but
neither in normal keratinocytes and in HaCaT cells nor in mela-
noma cells (MeWo melanoma cells) (Fritsch et al, 2001). The type
1 isotype of 3b -D5-HSD could exclusively be detected. By con-
verting androstenediol to testosterone, an intense enzyme activity
of 3b-D5-HSD was also revealed in the DP of human terminal
hair follicle (Ho¡mann et al, 2001). The enzyme activity did not
correlate with sebum excretion rate (Simpton et al, 1983) and the
enzyme expression did not vary with body site or sex (Sawaya
and Penneys, 1992).
17B-HSD
The last and key step in the formation of androgens and estrogens
is catalyzed by members of the family of 17b-HSD, whereas the
reduction step by 17b-HSD is essential for the formation of the
more active androgens and the oxidative reaction inactivates the
potent sex steroids. These events take place in the same cell where
synthesis occurs. The 17b-HSD thus provide each cell with the
means of precisely controlling the intracellular concentration of
each sex steroid according to local needs (Zouboulis, 2000a). To
date, seven types of human 17b-HSD have been cloned, se-
quenced, and characterized, designated types 1^7 in the chrono-
logic order of their isolation (Biswas and Russell, 1997; Labrie
et al, 1997; Krazeisen et al, 1999; Pelletier et al, 1999). The type 1
17b-HSD (17b-HSD1), encoded in chromosome 17q21, is a cyto-
solic enzyme that was found in ovary, placenta, and in breast can-
cer cells. 17b-HSD2, encoded in chromosome 16q24, is a
microsomal enzyme that was found in placenta, endometrium,
normal breast cells, prostate, liver, small intestine, kidney,
pancreas, and colon. 17b-HSD3, encoded in chromosome 9q22,
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was only detected in testis and its importance in male steroid hor-
mone physiology was underscored by its de¢ciency in a form of
male pseudohermaphroditism, the only genetic mutation of these
group described until now (Andersson and Moghrabi, 1997). 17b-
HSD4 is a peroxisomal enzyme with its mRNA mainly ex-
pressed in liver, heart, prostate, testis, and prostate cancer cell
lines. 17b-HSD5, encoded in chromosome 10p14,15, was found in
the placenta, ovary, endometrium, mammary gland, testis, liver,
skeletal muscle, and skin (Labrie et al, 1997, 2000b; Pelletier et al,
1999; Qin and Rosen¢eld, 2000). 17b-HSD6, isolated by expres-
sion cloning of rat and human prostate, oxidizes 5a-androstane-
3a, 17b-diol[3a -androstanediol (3a-Adiol)], to androsterone (Bis-
was and Russell, 1997). It is a member of the short chain dehydro-
genase/reductase family and shares 65% sequence identity with
retinol dehydrogenase 1 (RoDH1), which catalyzes the oxidation
of retinol to retinal. Expression of rat and human RoDH cDNA
in mammalian cells is associated with the oxidative conversion of
3a -Adiol to 5a-DHT. Thus, 17b-HSD6 and RoDH play oppos-
ing roles in androgen action; 17b-HSD6 inactivates 3a -Adiol by
conversion to androsterone and RoDH activates 3a-Adiol by
conversion to 5a-DHT (Biswas and Russell, 1997). The multisub-
strate nature of these short chain dehydrogenase/reductase en-
zymes allows for retinoid/steroid interactions (Napoli, 2001). It is
unknown if these interactions could partially explain the speci¢c
anti-proliferative e¡ect of isotretinoin (13-cis retinoic acid) on se-
bocytes, whose growth and di¡erentiation is strongly in£uenced
by androgens (Zouboulis et al, 1994; Tsukada et al, 2000). The hu-
man 17b-HSD7 shows 78% and 74% amino acid identity with
rat and mouse 17b-HSD7, respectively.These enzymes are respon-
sible for estradiol production in the corpus luteum during preg-
nancy, but are also present in placenta and several steroid target
tissues (breast, testis, and prostate) as revealed by reverse tran-
scription^polymerase chain reaction (Krazeisen et al, 1999). Re-
cently, 17b-HSD8, also known as Ke6 gene found in the HLA
region, was shown to be able to transform e⁄ciently estradiol to
estrone in transfected HEK-293 cells (Luu-The, 2001). On the
whole, the type 1, 3, 5, and 7 isoenzymes, using NADPH as co-
factor, seem to reduce weak steroid hormones to more potent
ones (e.g., DHEA into androstenediol, androstenedione to testos-
terone, 5a-androstanedione to 5a-DHT, estrone to estradiol),
whereas type 2, 4, 6, and 8 isoenzymes, using NADþ as cofactor,
work in the opposite oxidizing direction and seem to play a gen-
eral role in the peripheral inactivation of androgens (Labrie et al,
1997; Luu-The, 2001). Only the 17b-HSD3, however, is responsi-
ble for pseudohermaphroditism in de¢cient boys.
The cutaneous expression of 17b-HSD was mainly demon-
strated in the pilosebaceous unit and epidermal keratinocytes. In
hair follicles, 17b-HSD was histochemically localized to outer
root sheath cells (ORS) (Crovato et al, 1973). The fresh plucked
anagen hairs mainly containing keratinocytes from the inner root
sheath and ORS expressed very high levels of 17b-HSD2 and
moderate levels of 17b-HSD1 (Courchay et al, 1996). This is
compatible with the early studies showing androstenedione as
the major metabolite of cultured human hair follicle keratino-
cytes incubated with radiolabeled testosterone (Dijkstra et al,
1987; Sonada et al, 1993). The human sebaceous gland possesses
the cellular machinery needed to transcribe the genes for the type
1^5 isoenzymes of 17b-HSD (Thiboutot et al, 1998; Labrie et al,
2000b), among them a strong signal of 17b-HSD2 mRNA was
detected (Fritsch et al, 2001). At the protein level, the type 2
isoenzyme of greater oxidative activity predominates in intact
sebaceous glands, suggesting its protective role against the e¡ects
of excessive amounts of potent androgens in vivo (Thiboutot et al,
1998). Greater reductive activity of 17b-HSD was noted in sebac-
eous glands from facial areas compared with acne non-prone
areas, suggesting an increased net production of potent androgens
in facial areas (Thiboutot et al, 1998) and human sebocytes but not
keratinocytes expressing 17b-HSD3, undersigning the major reg-
ulatory role of the sebaceous gland in androgen metabolism in
the skin (Fritsch et al, 2001). The speci¢c localization and impor-
tance of 17b-HSD2 in the physiology of sebaceous gland seems to
be circumstantially evidenced by the description of ‘‘normal’’ de-
velopment of pubertal acne and male distribution of body hair in
male pseudohermaphroditism due to 17b-HSD3 de¢ciency syn-
drome (Saez et al, 1971;Virdis et al, 1978). Noteworthy is the report
of a distinct syndrome of alopecia totalis (actually atrichia),
ichthyosis and male pseudohermaphroditism due to steroid 17b-
HSD de¢ciency in an Israeli-Arab newborn infant (Kauschansky
et al, 1998).
17b-HSD enzyme activity was also shown in cultured epider-
mal keratinocytes (Itami and Takayasu, 1981; Dijkstra et al, 1987;
Hughes et al, 1997; Fritsch et al, 2001) and in the microdissected
apocrine sweat gland (Sonada et al, 1993). In primary cultured ker-
atinocytes, which predominantly converted estradiol to estrone,
mRNA expression of the type 1, 2, and 4 17b-HSD isoenzymes
was detected and treatment with 1,25-dihydroxyvitamin D3 up-
regulated the type 2 mRNA (Hughes et al, 1997). In HaCaT cells,
a commonly used keratinocyte cell line, however, only the type 2
isoenzyme was detected (Fritsch et al, 2001).
5a-REDUCTASE
5a-reductase is the enzyme that catalyzes the conversion of tes-
tosterone to 5a-DHT. The conversion of testosterone to 5a-
DHT ampli¢es the androgenic signal through two mechanisms:
(i) 5a-DHT, unlike testosterone, cannot be aromatized to estro-
gen, thus its e¡ect remains purely androgenic, and (ii) in vitro 5a-
DHT binds to the human androgen receptor with greater a⁄nity
than testosterone does, and the 5a-DHT/androgen receptor com-
plex appears to be more stable (Anderson and Liao, 1968). Over
the last decade, molecular cloning studies have characterized two
genes that encode two isoenzymes of 5a-reductase, namely, type
1 and type 2; the former exists predominantly in the skin,
whereas the latter in the prostate (Andersson and Russell, 1990;
Andersson et al, 1991). Genetically, the type 1 isoenzyme is en-
coded by the SRD5A1 gene on the distal arm of chromosome 5
(band p15), whereas the type 2 isoenzyme by the SRD5A2 gene
on chromosome 2 (band p23) (Russell and Wilson, 1994). Both
genes contain ¢ve exons separated by four introns. Both isoen-
zymes are hydrophobic with approximately 50% identity in their
amino acid sequences.Whereas type 1 5a-reductase has a broad
alkaline pH optima of 6.0^8.5 and demonstrates relatively moder-
ate a⁄nity for steroid substrates (Km: 1^5 mM), the type 2 5a-re-
ductase has a narrow acidic pH optima of 5.0^6.0 and
demonstrates high a⁄nity for substrates (Km: 4^50 nm) (Russell
and Wilson, 1994). These di¡erent enzyme kinetics may have
some important implications for disease states. Cutaneous distri-
bution of type 1 isoenzyme in vivo was immunohistochemically
identi¢ed in sebaceous glands, epidermis, eccrine sweat glands,
apocrine sweat glands (in normal ones as well as in people with
osmidrosis), and hair follicles (ORS, DP, matrix), as well as in the
endothelial cells of small vessels and the Schwann cells of cuta-
neous myelinated nerves (Luu-The et al, 1994; Eicheler et al, 1995;
Courchay et al, 1996; Sato et al, 1998). In the skin the activity of the
type 1 5a-reductase is concentrated in sebaceous glands and is
signi¢cantly higher in sebaceous glands from the face and
scalp compared with nonacne-prone areas (Thiboutot
et al, 1995). In vitro, type 1 5a-reductase was detected in the cyto-
plasm of cultured human sebocytes, keratinocytes and HaCaT
cells, ¢broblasts, dermal microvascular endothelial cells, hair DP
cells from various body sites, melanocytes, and melanoma cells
(Chen et al, 1998a, b; Ando et al, 1999; Fritsch et al, 2001). Northern
blot studies revealed most abundant type 1 mRNA in neonatal
foreskin keratinocytes, followed by adult facial sebocytes, and
stronger expression in DP from occipital hair cells than from
beard (Chen et al, 1998a).
Within hair follicles, prominent immunostaining of type 2
5a-reductase was localized in the inner layer of ORS, inner root
sheath, the infundibulum of hair follicle, and sebaceous ducts
(Bayne et al, 1999). Regional studies showed the type 2 mRNA
present in beard DP, but absent from occipital scalp and axillary
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DP (Ando et al, 1999). The type 2 isoenzyme in beard DP has
three times higher activity than the type 1 5a-reductase present
in the occipital scalp and axillary DP (Itami et al, 1994; Eicheler
et al, 1998). The speci¢c activity of 5a-reductase in the hair DP
exceeded those in other hair follicle compartments (connective
tissue sheaths and ORS) by a factor of at least 14 in the scalp and
at least 80 in the beard (Eicheler et al, 1998). The beard DP cells
appeared to generate more 5a-DHT than those from nonbalding
scalp hair follicles (Thornton et al, 1993); however, the individual
freshly isolated intact DP was shown to possess considerably
di¡erent levels of ex vivo enzyme activities (Niiyama et al, 2000).
Taken together, whereas the type 1 5a-reductase has been de¢-
nitely demonstrated in sebaceous glands, the isoenzyme distri-
bution in hair follicles is less well-de¢ned, probably due to:
(i) physiologic variation of the enzyme activity in di¡erent body
regions; (ii) utilization of di¡erent polyclonal/monoclonal anti-
bodies; and (iii) inadequate assessment of enough specimens.
More evidence is needed to de¢ne better the existence of the type
1 isoenzyme in hair follicles (Luu-The et al, 1994; Eicheler et al,
1995; Chen et al, 1998a; Ando et al, 1999; Bayne et al, 1999) and
the precise localization of the type 2 isoenzyme within the hair
follicles (in ORS or in DP) (Ho¡mann and Happle, 1999; Bayne
et al, 1999).
CYTOCHROME P450 19 (AROMATASE)
Aromatase, the product of the CYP19 gene, catalyzes three conse-
cutive hydroxylation reactions converting C19 androgens to C18
estrogens. It belongs to the cytochrome P450 superfamily of en-
zymes, which contains 36 gene families and over 300 character-
ized members (Simpson et al, 1997). Recently, aromatase has been
reported to be present in various extragonadal tissues and its ex-
pression is regulated in part by means of tissue-speci¢c promoters
through the alternative splicing mechanism on multiple exons 1
(Simpson, 2000a). At least six variants of exon 1 have been de-
scribed; exons 1a, 1b, 1c, 1d, 1e, and 1f that are speci¢c for expres-
sion in the placenta, skin ¢broblasts/fetal liver/adipose tissue/
vascular tissue, ovary, ovary/prostate, placenta, and fetal brain, re-
spectively (Harada, 1998, 1999). By immunohistochemical exami-
nation, aromastase was found in the ORS of anagen, terminal
hair follicles, and in sebaceous glands, but rarely in telogen hair
follicles. The expression did not vary with body site or sex in
normal subjects, but seemed to di¡er in patients with androge-
netic alopecia (Sawaya and Penneys, 1992; Sawaya and Price,
1997; see later). Semiquantitative reverse transcription^polymerase
chain reaction methods, however, showed poor expression of ar-
omatase in the plucked hair containing ORS and inner root
sheath keratinocytes (Courchay et al, 1996).The aromatase enzyme
activity has also been demonstrated in keratinocytes cultured in
serum-free medium (Hughes et al, 1997), ¢broblasts from both
genital and nongenital skin (Svenstrup et al, 1990), and ¢broblasts
from adipose tissue (Rink et al, 1996). In most tissues, aromatase is
induced by cyclic adenosine monophosphate or factors utilizing
cyclic adenosine monophosphate as a second messenger, whereas
androgens and glucocorticoids have been shown to be able to
stimulate the expression or activity of aromatase (Stillman et al,
1991; Zhao et al, 1995; Harada, 1999). To understand better the
clinical signi¢cance of aromatase in androgen-dependent derma-
toses, it would be interesting to study patients a¡ected with aro-
matase de¢ciency or excess syndromes to observe the occurrence
of acne or androgenetic alopecia (Simpson, 1998, 2000b; Bulun
et al, 1997; Bulun, 2000).
3a-HSD
Mammalian 3a-HSD regulate steroid hormone levels. Hepatic
3a-HSD inactivate circulating androgens, progestins, and
glucocorticoids by catalyzing the conversion of 3-ketosteroids to
3a-hydroxy compounds, e.g., the transformation of 5a-DHT
into 3a -Adiol. In the prostate, it acts as a molecular switch
and controls the amount of 5a-DHT that can bind to the andro-
gen receptor, whereas in the brain 3a-HSD can regulate the
amount of tetrahydrosteroids that can alter g-aminobutyric acid
receptor function (Penning et al, 1997). Molecular cloning indi-
cates that these mammalian 3a-HSD are highly homologous
proteins, prefer NADPH as cofactors and belong to the aldo-keto
reductase superfamily, including also 17b-HSD5, ovarian 20a-
HSD as well as the steroid 5b-reductases (Dufort et al, 1996; Pen-
ning 1999). The human type 1 and type 3 isoenzymes, sharing
81.7% identity, both e⁄ciently catalyze the transformation of
5b-DHT into 3a -Adiol in intact vector-transfected transformed
human embryonic kidney cells (Dufort et al, 1996, 2001). The hu-
man type 1 3a-HSD is expressed exclusively in the liver, whereas
the type 3 is more widely expressed in the liver, adrenal, testis,
brain, prostate, and HaCaT keratinocytes. The expression of the
type 2 3a-HSD was shown in the human prostate, and there it
inactivated 5a-DHT through its 3-ketosteroid reductase activity
(Lin et al, 1997).
Early studies showed the enzyme activity of 3a-HSD in cul-
tured human skin ¢broblasts and the 5a-DHT reduction is three
times higher in ¢broblasts from genital areas than from nongeni-
tal areas (Sultan et al, 1983). The expression of 3a-HSD mRNA
has been demonstrated in sebocytes (SZ95), keratinocytes (HaCaT
cells), and melanoma cells (MeWo), but the isotype has not yet
been identi¢ed (Fritsch et al, 2001). Keratinocytes were found to
inactivate tissue active androgens in a more pronounced manner
than sebocytes do by engagement of 3a-HSD (Fritsch et al, 2001).
Clinically, it is still controversial if serum levels of 3a-Adiol con-
jugates (3a-Adiol glucuronide or 3a-Adiol sulfate) serve as reliable
indicator for cutaneous 5a-DHT formation (see later, Lookingbill
et al, 1988a; Horton, 1992; Vogt et al, 1992), or are just a marker of
adrenal steroid production and metabolism (Rittmaster, 1995). In-
terestingly, rat liver 3a-HSD was found to be a target for nonster-
oidal anti-in£ammatory drugs (Pawlowski et al, 1991).
Cutaneous distribution of steroidogenic isozymes is summar-
ized inTable I.
Table I. Cutaneous distribution of steroidogenic isozymes
Isoenzymes/major
cutaneous isoenzyme
Encoding genes of the
cutaneous isoenzyme
Cutaneous distribution
Steroid sulfatase ? chromosome Xp22 K, F, DP
3b-HSD Types 1 and 2/Type 1 chromosome 1p13.1 SG
17b-HSD Types 1-7/Type 2 chromosome 16q24 SG, K, A
5a-reductase Types 1-2/Type 1 chromosome 5p15 SG, K, F, En, M, A, Ec, DP, ORS
Aromatase ? chromosome 15q21 SG, ORS, K, F
3a-HSD Types 1-3/Type 3? chromosome 10p15 SG, K, M, F
? Not known, HSD: hydroxysteroid dehydrogenase, K: keratinocytes, F: ¢broblast, DP: hair dermal papilla, SG: sebaceous glands, A: apocrine sweat gland, Ec: eccrine
sweat gland, En: vascular endothelial cells, M: melanocytes, ORS: outer root sheath
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ANDROGEN-DEPENDENT DERMATOSES
Acne vulgaris Decades of investigation have ¢rmly established
that the development and secretory activity of sebaceous glands
are strikingly in£uenced by hormones, especially androgens, and
that the sebaceous glands at the same time dominates cutaneous
androgen production (Pochi and Strauss, 1974; Zouboulis et al,
1998, 2002; Zouboulis 2000a). The distribution of various
hydroxysteroid dehydrogenases in human sebaceous glands and
their strong activities in acne-prone skin in comparison with
nonacne-prone skin areas have long since been evaluated (Baillie
et al, 1966).
Strong steroid sulfatase immunoreactivity in the acne
skin, primarily associated with the monocytes in¢ltrating the
lesions, but not in una¡ected skin was observed. The
enzymatic hydrolysis of DHEA-S to DHEA and of estrone
sulfate to estrone in cultured epidermal keratinocytes
has been demonstrated (Milewich et al, 1990). There were no
di¡erences in the rates of enzymatic hydrolysis of steroid
sulfatase in the epidermis of acne-prone and nonacne-prone
skin; however, the rate of estrone sulfate hydrolysis was two to
eight times greater than that of DHEA-S in all of the tissues
evaluated.
Signi¢cant di¡erences in the activity of 5a-reductase or 17b-
HSD in sebaceous glands regarding the presence of acne were
neither noted in men nor in women (Thiboutot et al, 1999). The
activity of 5a-reductase or 17b-HSD was signi¢cantly greater in
sebaceous glands from men than women. Higher serum
androgen levels were signi¢cantly higher in women with acne,
whereas no di¡erences were noted in men on the basis of the
presence of acne.
The exclusive predominance of the type 1 5a-reductase
in sebaceous glands and the major in£uence of local
androgenesis on sebum production were further con¢rmed
by two clinical observations: (i) adult males with type 2
5a-reductase de¢ciency had sebum production scores identical
to normal age-matched males; (ii) males with benign prostate
hyperplasia treated with ¢nasteride (5mg per day for 1 y)
did not decrease the sebum score from baseline values,
although the serum 5a-DHT level was lowered (Imperato-
McGinley, 1993). Moreover, the activity of the type 1
5a-reductase exhibits regional di¡erences in isolated sebaceous
glands (Thiboutot et al, 1995), which seemed to correlate with
the ¢nding that the stimulatory e¡ect of 5a-DHT on cell
proliferation, was more prominent on facial than on nonfacial
sebocytes (Akamatsu et al, 1992). In normal hair follicles and in
open and closed comedones, the type 2 isoenzyme was
demonstrated to localize within the companion layer of the
follicle (innermost layer of the ORS). In in£ammatory acne
lesions, the type 2 isozyme localized to the companion layer of
hair follicles and endothelial cells within the surrounding
in£ammatory in¢ltrate, but not to sebaceous glands
(Thiboutot et al, 2000). As 5a-DHT could enhance 5a-reductase
mRNA and enzyme activity in a feed-forward regulation
(Russell andWilson, 1994), and the type 2 isoenzyme has higher
a⁄nity for testosterone than the type 1 isoenzyme, the up-
regulated type 2 isoenzyme in the diseased state might contribute
to the aggravation of the pre-existing ‘‘hyperandrogenic’’
condition.
The role of 3a-HSD in the pathogenesis of acne has
rarely been addressed; the elevated plasma level of 3a -Adiol
glucuro-nide might merely re£ect the increased production of
5a-DHT, decreased local enzyme activity of 3a-HSD to
metabolize 5a-DHT, or both. It is not known if di¡erent
levels of 3a -HSD occur between men and women, between
acne and nonacne subjects or between mild (papulopustular)
acne and severe (nodulocytic) acne patients. In women with
mild to moderate acne, plasma 3a -Adiol glucuronide was
suggested to be the most sensitive marker (Lookingbill
et al, 1985), whereas the levels were shown to be decreased or
within normal range in other studies (Toscano et al, 1993;
Joura et al, 1996). Exaggerated androsterone metabolism,
however, was observed in hype-randrogenic as well as in some
normo-androgenic women with acne (Carmina et al, 1991;
Carmina and Lobo, 1993), and androsterone glucuronide/sulfate
seemed to be a better marker than 3a -Adiol glucuronide in
di¡erentiating acne and hirsutism in hyperandrogenic women
(Carmina et al, 1991). In young men, a statistically signi¢cant
correlation was found between serum 3a -Adiol glucuronide and
chest hairiness, acne as well as a combined chest hairiness and
acne score (Lookingbill et al, 1988b). Noteworthy was the
decreased serum levels of 3a -Adiol glucuronide in 24 acne
subjects (15 men and nine women) treated with 1mg
isotretinoin per kg bodyweight per day for 20 wk (Lookingbill
et al, 1988a).
It is also interesting to note that MPV-2213, a novel
nonsteroidal competitive inhibitor of aromatase, could lead to
the adverse e¡ect of acne formation in healthy male subjects
(Ahokoski et al, 1998), which sheds light on the possible role of
aromatase in the pathophysiology of acne formation.
Androgenetic alopecia Androgenetic alopecia can be de¢ned
as a 5a-DHT-dependent process with continuous miniaturization
of androgen sensitive hair follicles (Ho¡mann and Happle, 2000).
The intrafollicular conversion of testosterone to 5a-DHT seems
to play a central part leading to androgenetic hair loss.
Because steroid sulfatase plays an important part in androgen
metabolism, and elevated levels of DHEA have been reported in
young men with androgenetic alopecia, the hypothesis was
advanced that men with X-linked recessive ichthyosis do not
show androgenetic alopecia or develop only mild forms of
common baldness (Happle and Ho¡mann, 1999). A recent
clinical survey, however, did not support this hypothesis that X-
linked recessive ichthyosis and androgenetic alopecia are mutually
exclusive, in as much as advanced androgenetic alopecia was
found among these men (Trueb and Meyer, 2000).
Homogenates of sebaceous glands from a balding scalp had
greater 3b-HSD activity than those from a hairy scalp (Sawaya
et al, 1988). There is no data about the activity of 3b -HSD in
hair follicles from hairy vs balding scalp. Isolated intact hair
follicles and sebaceous glands from balding frontal scalp,
compared with a nonbalding occipital scalp, of patients with
androgenetic alopecia demonstrated increased activity of 17b-
HSD (Sawaya, 1991).
Both women and men with androgenetic alopecia have higher
levels of androgen receptors and 5a-reductase type 1 and 2 in
frontal than in occipital hair follicles, whereas higher levels of
aromatase were found in their occipital follicles (Sawaya and
Price, 1997). Aromatase content in women’s frontal hair follicles
was six times greater than in frontal hair follicles in men.
Frontal hair follicles in women had 3 and 3.5 times less 5a-
reductase type 1 and 2, respectively, than frontal hair follicles in
men (Sawaya and Price, 1997). Finasteride, a speci¢c competitive
inhibitor of type 2 5a-reductase, maximally decreased both scalp
skin and serum 5a-DHTat doses as low as 0.2mg per day (Drake
et al, 1999). Minoxidil was lately shown to increase 17b-HSD and
5a-reductase activity of cultured human DP from balding scalp
(Sato et al, 1999), the relevant signi¢cance of which remains
unclear.
A disorder of androgen conjugation, favoring sulfurylation
over glucuronidation, has been suggested to be a characteristic
feature in men and women with androgenetic alopecia (Legro et
al, 1994).Women with female pattern baldness were noted to have
a marked increase in the 3a-Adiol glucuronide/sex hormone
binding globulin ratio and low serum level of sex hormone
binding globulin (De Villez and Dunn, 1986).
In summary, the current understanding of androgenetic
alopecia focuses on the excessive in situ conversion of testo-
sterone to 5a-DHT, which involves the hyperactivity of 5a-
reductase and 17b-HSD, coupled with hypoactivity of aromatase
and overexpression of androgen receptors in balding vs
nonbalding scalps (Kaufman, 1996). 5a-DHT was currently
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shown to induce apoptosis in DP in vitro via a bcl-2 related
pathway.3 The roles of steroid sulfatase, 3b-D5-HSD and 3a -
HSD merit further studies. The molecular steps involved in
androgen-dependent beard growth vs androgen-dependent hair
miniaturization in androgenetic alopecia remain obscure
(Ho¡mann and Happle, 2000). The newly emerging interest in
the function of sebaceous glands in follicular biology (Sundburg
et al, 2000; Zouboulis et al, 2002) may arouse the re-evaluation of
the role of sebaceous glands in the peripheral hyperandrogenism
occurring in androgenetic alopecia (Dijkstra et al, 1987; Sawaya
et al, 1988; Zouboulis et al, 1994).
HIRSUTISM
The prevalence of hirsuties is di⁄cult to assess. Earlier studies es-
timated hirsutism a¡ects between 5 and 10% of women (Azziz
et al, 2000). Racial as well as social factors, and nowadays the
media, however, greatly determine the threshold level for nor-
mality of hair growth (Dawber and Sinclair, 2001). Hirsutism is
often seen in endocrine disorders characterized by hyperandro-
genesis as the result of abnormalities of either the ovaries or adre-
nal glands (Dawber and Sinclair, 2001). The diagnosis of
idiopathic hirsutism, when strictly de¢ned as hirsuteness with
normal ovulatory function and circulating androgen levels, will
include less than 20% of all hirsute women (Azziz et al, 2000).
Earlier studies showed in adult women the higher activity of
5a-reductase in the genital skin as compared with the dorsal skin
of the fetus as well as the abdominal skin, respectively (Flamigni
et al, 1971), and in hirsute women the increased 5a-reductase
activity in genital skin ( Jenkins and Ash, 1973; Sera¢ni and Lobo,
1985; Sera¢ni et al, 1985). Expression of both type 1 and type 2 5a-
reductase mRNAwas demonstrated in genital skin as well as in
pubic skin ¢broblasts, whereas the type 2 isoenzyme appeared to
predominate in pubic skin of normal men, normal women, and
hirsute patients (Mestayer et al, 1996). The e¡ectiveness of ¢naster-
ide (5mg per day) in the treatment of idiopathic and polycystic
ovary syndrome-associated hirsutism further signi¢es the role of
type 2 5a-reductase in the pathophysiology of hirsutism (Petrone
et al, 1999). As the circulating androgens are known to increase
peripheral 5a-reductase activity (Azziz et al, 2000), and as
previous studies mostly utilized whole skin tissue or cultured
¢broblasts, but not the individual hair follicle components,
however, more work is needed to de¢ne better the precise roles
of the di¡erent isoenzymes and their activities in the develop-
ment of hirsutism, especially the idiopathic hirsutism.
3a -Adiol conjugates (glucuronide or sulfate) were elevated in
hirsute compared with nonhirsute women (Carmina et al, 1991;
Toscano et al, 1993). Plasma (serum) concentrations of 3a -Adiol
glucuronide appeared to re£ect hirsutism most accurately
(Carmina et al, 1995a) and were elevated in polycystic ovary
syndrome patients with/without hirsutism and in patients with
idiopathic hirsutism (Kirschner et al, 1987; Falsetti et al, 1998). In
idiopathic hirsutism, the speci¢city of serum 3a -Adiol glucuro-
nide in re£ecting the peripheral 5a-reductase activity has been
questioned (Vermeulen and Giagulli, 1991; Gilad et al, 1994; Joura
et al, 1997). In women, levels of 3a -Adiol glucuronide essentially
re£ect adrenal precursor levels as well as 5a-reductase activity in
peripheral tissues (Vermeulen and Giagulli, 1991). The correlation
between the 3a-Adiol glucuronide and hirsutism score was
signi¢cant only in hirsute women with increased adrenal
androgen secretion (increased DHEA/DHEA-S) and in women
with idiopathic hirsutism. The correlation was not signi¢cant in
hirsute women with increased ovarian testosterone secretion
(Pang et al, 1992). In women with facial hirsutism, serum
3a -Adiol glucuronide concentrations had no correlation with
degree of facial hirsutism (Salman et al, 1992) and the levels
were no more often increased than the other androgen precursors
in women with mild to moderate hirsutism (Vermeulen
and Giagulli, 1991; Giagulli et al, 1991). Modi¢cations in peri-
pheral androgen activity (presumably through 5a-reductase
activity) were shown to be time-dependent, and serum 3a-Adiol
glucuronide seemed to re£ect changes after 6 mo of treatment.
(Carmina et al, 1995b). Overall, serum levels of 3a -Adiol
glucuronide appears to represent either adrenal androgen
production or skin 5 a-reductase activity (Paulson et al, 1986;
Rittmaster and Thompson, 1990). Although substantial evidence
indicated its signi¢cance in hirsute women with polycystic ovary
syndrome, the routine measurement of serum 3a-Adiol glucuro-
nide is not recommended in the evaluation of idiopathic hirsut-
ism or in other hirsute patients (Azziz et al, 2000), as this is
currently conceptualized to be due to peripherally regionalized
in situ hyperandrogenism.
Androsterone glucuronide/sulfates were also proposed to re-
£ect peripheral androgen metabolism (Matteri et al, 1989). In
women with idiopathic hirsutism or polycystic ovary disease,
androsterone glucuronide was found to be elevated and could
re£ect an increased production of adrenal androgens, but its level
did not correlate with the severity of hirsutism (Thompson et al,
1990). Androsterone sulfate, being the most abundant 5a-reduced
androgen metabolite in serum, however, was not recommended
as a marker of either adrenal androgen production or hirsutism
(Zwicker and Rittmaster, 1993; Azziz et al, 2000). Table II sum-
marizes the alterations of enzyme activity in androgen-dependent
dermatoses.
PHARMACOLOGIC DEVELOPMENT OF
STEROIDOGENIC ENZYME INHIBITORS
Steroid sulfatase inhibitors As androgens and estrogens may
be synthesized inside the cells (or cancer cells) utilizing the
circulating systemic precursors DHEA-S and estrone sulfate,
therapeutic agents targeted to inhibit steroid sulfatase activity
may have therapeutic potential for androgen-sensitive and
estrogen-sensitive diseases. Many novel compounds have been
developed and evaluated mainly for the treatment of breast
cancer (Billich et al, 2000; Chetrite and Pasqualini, 2001).
Steroidal inhibitors may include 17a-substituted benzyl-estradiols,
3-O-sulfamate estrone, 2-methoxyestrone-3-O-sulfamate, the
combination of two substituents at positions C3 and C17a of
estradiol 3-O-sulfamate, e.g., 17a-benzyl (or 40 -tert-butylbenzyl)
estra-1,3,5(10)-trienes and 17a-derivatives of estradiol, 17b-(N-
alkylcarbamoyl)-estra-1,3,5(10)-trien-3-O-sulfamates, and 17b-(N-
alkanoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (Woo et al, 1998;
Li et al, 1998; Ciobanu et al, 1999; Boivin et al, 2000; Purohit et al,
2001). Nonsteroidal sulfamates such as ( p-O-sulfamoyl)-N-
alkanoyl-tyramines, tricyclic coumarin sulfamates, tricyclic
oxepin sulfamate, and substituted chromenone sulfamates (e.g.,
sulfamic acid 2-t-butyl-4-oxo-4H-chromen-6-yl ester) have
been described (Billich et al, 2000; Purohit et al, 2001).
Table II. Enzyme activity in androgen-dependent dermatoses
Acne Androgenetic
alopecia
Hirsutism
Steroid sulfatase m (Mo) ? ?
- (K)
3b-HSD ? m (SG, HF) ?
17b-HSD -(SG) m(HF) ?
5a-reductase -(SG) m(HF) m(F)
Aromatase ? k(HF) ?
3a-HSD ? ? ?
? not known, m: increased, k: decreased,-: no di¡erence, SG: sebaceous gland;
K: keratinocytes, F: ¢broblast, Mo: monocytes, HF: hair follicle
3Wro¤ bel A, Mandt N, Hossini A, Seltmann H, Zouboulis ChC, Orfanos
CE, Blume-Peytavi U: 5a-Dihydrotestosterone and testosterone induce
apoptosis in human dermal papilla cells by downregulation of the bcl-2
pathway. J Invest Dermatol 115:581, 2000 (Abstr.)
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Estrone-3-O-sulfamate was shown to inhibit the steroid
sulfatase enzyme activity in a concentration-dependent manner
in human hair DP ex vivo (Ho¡mann et al, 2001).
3b-HSD inhibitors Known inhibitors used clinically in
dermatology include the gestagens cyproterone acetate,
norgestrel, norethisterone, which exhibit a dual activity by
parallel binding to a androgen receptor (Dumont et al, 1992;
Zouboulis et al, 1999). Trilostane (4a -5-epoxy-17b-hydroxy-3-
oxo-5a-androstan-2-carbonitrile) and cyanoketone (2a-
cyano-17b-hydroxy-4,4,17a-trimethylandrost-5-en-3-one) are
two classical steroidal inhibitors of type 1 3b -HSD (Cooke,
1996). Trilostane can attenuate the preovulatory gonadotropin
surge by inhibiting progesterone synthesis (Mahesh and Brann,
1998). It has also been clinically tried to treat Cushing’s
syndrome (Engelhardt and Weber, 1994). Iso£avonoids such as
genistein and daidzein were also shown to exert an anti-3b-
Table III. Speci¢c inhibitors of steroidogenic isoenzymes
Steroidogenic
enzymes
Isoforms Characterized inhibitors
Steroidal Non-steroidal
Steroid sulfatase 17a-substituted benzylestradiols tricyclic coumarin sulfamates
Estrone-3-O-sulfamate tricyclic oxepin sulfamate
2-methoxyestrone-3-O-sulfamate substituted chromenone sulfamates
17a-benzyl (or 40 -tert-butylbenzyl)estra-1,3,5(10)-trienes
17b-(N-alkylcarbamoyl)-estra-1,3,5(10)-trien-3-O-sulfamates
3b-hydroxysteroid Type 1 trilostane cyanoketone
dehydrogenase cyproterone acetate iso£avonoids (genistein)
norgestrel
norethindrone
Type 2 thiazolidinediones
17b-hydroxysteroid
dehydrogenase
Type 1 16-(bromoalkyl)-estradiols
£avonoids, iso£avonoids, lignans
tri£uoromethylacetylenic secoestradiol
6b-(thiaheptanamide) derivatives of estradiol
Type 2 estrone containing a spiro-gamma-lactone at position 17
7a-thioalkyl and 7a-thioaryl derivatives of spironolactone
N-butyl-N-methyl-11-(30 -hydroxy-210, 170-
carbolactone-190 -nor-170a-pregna-10,30, 50(100)-
trien-70a-yl)-undecanamide
£avonoids, iso£avonoids, lignans
Type 3 1,4-androstadiene-1,6,17- trione
androsterone 3b-substituted derivatives
5a-reductase Type 1 4-azasteroids (MK386)
6-azasteroidal 17b-carboxamide triaryls)
8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-
octaahydro-benzo[f] quinolin-3(2H)-
one (LY 191704)
6-[4-(N,N-diisopropylcarbamoyl)phenyl]-
N-methyl-quinolin-2-one 5)
benzo[c]quinolizin-3-ones
epicatechin-3-gallate,
epigallocatechin-3-gallate
suramin
zinc
azelaic acid
Type 2 ¢nasteride
turosteride
6-[4-(N,N-diisopropylcarbamoyl)phenyl]-
1H-quinolin-2-one 4
4-[3-[5-benzyl-8-(2-methyl)propyl-
10,11-dihydrodibenz[b,f]azepine-
2-carboxamido]phenoxy]butyric acid
MK-434
MK-963
dihydro¢nasteride
chlormadinone acetate
TZP-4238
epristeride (SK&F 105657, ONO-9302)
17a-estradiol
17-(50 -isoxazolyl)androsta-4,16-dien-3-one
Type 1/2 N-(1,1,1,3,3,3-hexa£uorophenyl-propyl)-3-oxo-
4-aza-5a-androst-1-ene-17b-carboxamide (PNU 157706)
benzoquinolinone
Serenoa repens extract permixon
dutasteride Artocarpus incisus
oxendolone (TSAA-291: 16 b-ethyl- iso£avonoids and lignans
17b-hydroxy-4-estren-3-one)
19-nor-10-azasteroids
alizarin and curcumin
phenazine derivatives
progesterone-based steroids bearing an oxime group myristoleic acid
connected to the steroidal D-ring g-linolenic acid
4-[3-[3-[bis(4 -isobutylphenyl)-
methylamino]benzoyl]-1H-indol-1-yl]
butyric acid (FK 143)
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HSD e¡ect (Le Bail et al, 2000). Thiazolidinediones was recently
shown to inhibit directly the steroidogenic enzymes P450c17 and
type 2 3b-HSD (Arlt et al, 2001).
17b-HSD inhibitors As the 17b-HSD system plays a key part
in the formation or inactivation of several active androgens and
estrogens from circulating precursors, these isoenzymes can
regulate tumor cell proliferation in androgen- and estrogen-
dependent cancers. Endocrine therapies for the treatment and
prevention of breast cancer are presently under intensive clinical
trials with the intention of developing dual-action compounds to
block estrogen action optimally by antagonizing the estrogen
receptor as well as inhibiting the estradiol biosynthesis
(Blomquist, 1995; Tremblay and Poirier, 1998).
As stated before, various 17b-HSD isoenzymes possess di¡erent
catalytic reductive or oxidative activity, thus design of speci-
¢c antagonist should aim at binding to hydrophilic and
cofactor-depending sites at the active center of the isoenzyme
(Krazeisen et al, 2001). Prior to better characterization of the
molecular genetics and physiology of di¡erent isoenzymes, the
exploration and development of speci¢c enzyme inhibitors were
performed depending on the selected tissues (liver, ovary,
Figure 2. Chemical structures of some representative steroidogenic enzyme inhibitors.
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placenta, testis or prostate, etc.) from di¡erent species under
examination (human vs rat, mouse or porcine). Speci¢city
of the compounds based on the analysis of these data seems
to be confounded by the ¢nding that the same organ/tissue
may contain more than one 17b-HSD isoenzyme (Luu-The,
2001).
Well characterized 17b-HSD1 inhibitors include estradiol
derivatives containing a bromopropyl/or iodopropyl group at
position 16a such as 16-(bromoalkyl)-estradiols (Luu-The et al,
1995; Tremblay et al, 1995), phytoestrogens such as £avonoids
(including £avone, £avanone, and iso£avone), iso£avonoids, and
lignans (Evans et al, 1995; Makela et al, 1995, 1998; Le Bail
Figure 2. (continued).
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et al, 1998), tri£uoromethylacetylenic secoestradiol (Lawate and
Covey, 1990), and 6b-(thiaheptanamide) derivatives of estradiol
(Poirier et al, 1998). Compounds belonging to this group might
also include those described to inactivate ovarian 17b-HSD
isoenzyme, such as glycyrrhizin and glycyrrhetinic acid
(Sakamoto and Wakabayashi, 1988; Armanini et al, 1999) or to
inhibit the enzyme activity in breast cancer cell lines, such as
medrogestone (Chetrite et al, 1999).
Well characterized 17b-HSD2 inhibitors containing a spiro-gs-
lactone at position 17 (Luu-The et al, 1995), 7a-thioalkyl and
7a-thioaryl derivatives of spironolactone such as 3-Oxo-17a-
pregna-4-ene-7a-{4-[2-(1-pipendiryl)ethoxy]-benzylthio} 21,17-
carbolactone (Tremblay et al, 1999), N-butyl-N-methyl-11-(30 -
hydroxy-210, 170-carbolac-tone-190 -nor-170a-pregna-10,30,50(100)-
trien-70a-yl)-undecanamide (Sam et al, 2000), £avonoids,
iso£avonoids, and lignans (Evans et al, 1995; Makela et al, 1998;
Le Bail et al, 1998). Based on the characterized tissue distribution
of the isoenzymes, included in this group might be compounds
that are able to work on:
1 The placenta: danazol; ethinylestradiol (Blomquist et al, 1984);
unsaturated fatty acids, such as oleic, arachidonic, linoleic, and li-
nolenic acid (Blomquist, 1985); periodate-oxidized NADPþ
(Mendoza-Hernandez et al, 1987); 14,15-secoestra-1,3,5(10)-trien-
15-ynes (Auchus, 1989); spiro-gp-lactones containing the C-18
nucleus (Sam et al, 1995); and chalcones, such as naringenin
chalcone and 4-hydroxychalcone (Le Bail et al, 2001).
2 Human benign prostatic hyperplasia tissue: testolactone
(Bartsch et al, 1987).
3 Liver microsomal enzymes: nonsteroidal anti-in£ammatory
agents and nonsteroidal estrogens, such as hexestrol, dienstrol,
diethylstilbestrol, and zearalenone (Hasebe et al, 1987); and reti-
noids (13-cis retinoic acid49-cis retinoic acid4 all-trans retinoic
acid) (Murray et al, 1994).
Well-characterized 17b-HSD3 inhibitors include 1,4 -androsta-
diene-1,6,17-trione (Luu-The et al, 1995) and androsterone 3b-sub-
stituted derivatives (Ngatcha et al, 2000). Included might also be
those reported to inhibit testicular 17b-HSD enzyme activity,
such as licorice (glycyrrhizin and glycyrrhetinic acid) (Sakamoto
andWakabayashi, 1988; Armanini et al, 1999), losulazine (Ray et al,
1994), amphetamine (Tsai et al, 1997), methotrexate (Badri et al,
2000), and S-petasine (like a sesquiterpene ester, being an anti-
in£ammatory analgesic component of the butterbur, Petasites
hybridus; Lin et al, 2000).
5a-reductase inhibitors Development of speci¢c 5a-reductase
inhibitors began soon after 5a-DHT was reported to be the
major androgen acting in the periphery (Liang et al, 1983, 1984).
Great progress has since been made and continuing interests
grow in developing more potent and speci¢c 5a-reductase
inhibitors. As 5a-DHT, being two to 10 times stronger than
testosterone in androgenicity, was supposed to play a more
important part than testosterone in many androgen-dependent
diseases (benign prostata hyperplasia, prostatic carcinoma,
acne, androgenetic alopecia, hirsutism; Chen et al, 1996;
Bartsch et al, 2000), whereas speci¢c inhibition of its formation
would bring the advantage of sparing the anti-virilizing
side-e¡ects of general androgen receptor blockers (e.g.,
£utamide). Inhibitors can be classi¢ed based on the chemical
structures of steroidal vs nonsteroidal inhibitors or according to
the isoenzyme speci¢city as type 1, type 2 and type-1/2
dual inhibitors (Chen et al, 1996; Zouboulis, 2000b). It was
noticed that the Ki values vary depending on the species
examined (human vs rat) and the cell/tissue origin tested
(e.g., testis vs prostate or primary culture vs cell lines). Except
for ¢nasteride, most of these synthetic chemicals or
phytotherapeutic agents are still undergoing in vitro tests, animal
studies, or clinical trials (Zouboulis, 2000b). Finasteride, a speci¢c
type 2 5a-reductase competitive inhibitor, is the ¢rst systemic
drug approved for clinical use and has been shown to be
e¡ective for the treatment of androgenetic alopecia in young to
middle-aged men as well as aged men between 53 and 76 y, but
not in post-menopausal women (Brenner and Matz, 1999;
Whiting et al, 1999).
Speci¢c type 1 inhibitors include certain steroidal inhibitors,
such as 4-azasteroids (e.g., MM-386: 4,7b-dimethyl-4 -aza-5a-
cholestan-3-one) or 6-azasteroidal 17b-carboxamide triaryls
(Li et al, 1995), and nonsteroidal inhibitors benzoquinolinones
(LY 191704: 8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octaahydro-
benzo[f]quinolin-3(2H)-one), 6-[4 -(N,N-diisopropylcarbamoyl)
phenyl]-N-methyl-quinolin-2-one 5) (Baston et al, 2000), benzo
[c]quinolizin-3-ones (Guarna et al, 2000), certain plant extracts,
such as green tea extract catechins (epicatechin-3-gallate and
epigallocatechin-3-gallate) (Liao and Hiipakka, 1995), and
suramin, zinc, and azelaic acid (Chen et al, 1996). MK-386, an
azasteroid that speci¢cally inhibits the type 1 5a-reductase
in vitro, was shown to suppress sebum as well as serum 5a-DHT
in a concentration-dependent manner (Schwartz et al, 1997;
Baston et al, 2000).
Speci¢c type 2 inhibitors, in addition to ¢nasteride, include
4-methyl-4 -azasteroids (e.g., turosteride: 1-(4 -methyl-3-oxo-
4-aza-5a-androstane-17b-carbonyl)-1,3-diisopropylurea, or MK-
963: [5a-23-methyl-4-aza-21-norchol-1-ene-3,20-dione])4 (Chen
et al, 1996), 4-azasteroids (e.g., MK-434: 17b-benzoyl-4 -aza-5a-
androst-1-en-3-one, dihydro¢nasteride)4 (Chen et al, 1996;
Zouboulis, 2000b), chlormadinone acetate (Nukui, 1997), osaterone
acetate (TZP-4238: 17a-acetoxy-chloro-2-oxa-4,6-pregnadiene-
3,20-dione) (Takezawa et al, 1992), epristeride (SK&F 105657 or
ONO-9302: N-(t-butyl)androst-3,5-diene-17b-carboxamide-
3-carboxylic acid,) (Levy et al, 1994), 17a-estradiol (Hevert,
2000), 6-Methylenesteroidal derivatives (Li et al, 1995), 17-
(50 -isoxazolyl)androsta-4,16-dien-3-one (L-39) (Nnane et al,
2000), nonsteroidal compounds such as 6-[4 -(N,N-diisopro-
pylcarbamoyl)phenyl]-1H-quinolin-2-one 4 (Baston et al,
2000), and tricyclic compounds such as 4-[3-[5-benzyl-8-(2-
methyl)propyl-10,11-dihydrodibenz[b,f ]azepine-2-carboxamido]
phenoxy]butyric acid (Takami et al, 2000), etc.
Several novel compounds with potent dual inhibitory activity
on both type 1 and type 2 isoenzymes have been reported.
Steroidal antagonists include N-(1,1,1,3,3,3-hexa£uorophenyl-
pro-pyl)-3-oxo-4-aza-5a-androst-1-ene-17b-carboxamide (PNU
157706) (di Salle et al, 1998) dutasteride (Frye et al, 1998;
Gisleskog et al, 1998), oxendolone (TSAA-291: 16b -ethyl-17b-
hydroxy-4-estren-3-one) (Sudo et al, 1981; Li et al, 1995), 19-nor-
10-azasteroids (Guarna et al, 1997), and progesterone-based
steroids bearing an oxime group connected to the steroidal
D-ring (Hartmann et al, 2000). Nonsteroidal compounds
include benzoquinolinone (e.g., LY320236) (McNulty et al,
2000), plant extracts such as Serenoa repens extract permixon
(Bayne et al, 2000), Artocarpus incisus (Shimizu et al, 2000),
iso£avonoids and lignans (Evans et al, 1995), alizarin and
curcumin (Liao et al, 2001), phenazine derivatives
(e.g., ribo£avin) (Li et al, 1995), myristoleic acid (Liao et al, 2001)
and g-linolenic acid (Liang and Liao, 1992, 1997; Liao and
Hiipakka, 1995), indole derivatives such as 4-[3-[3-[bis(4 -
isobutylphenyl)-methylamino]benzoyl]-1H-indol-1-yl] butyric
acid (FK 143) (Katashima et al, 1998), sodium-4-[2-(2,3-
dimethyl-4-and 2 over black square); [1 and 2 over black
square]-(4- isobutylphenyl)ethoxy]benzolamino]phenoxy] butyrate
(ONO-3805) (Takahashi et al, 1992), indoline and aniline
derivatives (Igarashi et al, 2000). g-Linolenic acid was shown
to inhibit testosterone-stimulated £ank organ growth
but not 5a-DHT-stimulated £ank organ growth (Liang and
Liao, 1997). CS-891 inhibits 5a-reductase activity in freshly
isolated DP of human hair follicles (Niiyama et al, 2000). It
remains to be determined if these dual inhibitors can further
decrease the tissue 5a-DHT level and are clinically more
e¡ective than ¢nasteride in the treatment of male androgenetic
alopecia.
4Sei¡ert K, Fritsch M, Zoubouls ChC: 5a-reductase inhibitors exhibit
distinct e¡ects on human keratinocytes and sebocytes in vitro. J Invest Der-
matol 110:550, 1998 (Abstr.)
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Table III and Figure 2 show the representative speci¢c
steroidogenic enzyme inhibitors and their chemical structures,
respectively.
CONCLUSIONS
Similar to the classical steroidogenic organs, such as gonads
and adrenal glands, the skin and its appendages, including
hair follicles, sebaceous glands, and eccrine/apocrine glands,
are armed with all the necessary enzymes required for
androgen synthesis and metabolism. Steroid sulfatase, 3b-HSD1,
17b-HSD3, and the type 1 5a-reductase are the major
steroidogenic enzymes responsible for the formation of potent
androgens, whereas 17b-HSD2, 3a-HSD, and aromatase seem to
inactivate the excess androgens locally in order to achieve
androgen homeostasis (Fritsch et al, 2001). Small levels of some
isoenzymes found in normal states, may have important
implications in disease states, where these factors may be
upregulated, contributing to the exaggeration of ‘‘peripheral
hyperandrogensim’’. Clari¢cation of the cutaneous expression
and tissue-speci¢c regulation of these steroidogenic isoenzymes
could help us to understand better their roles in the growth
and development of the skin as well as the pathophysiology of
androgen-dependent dermatoses. Finasteride is the ¢rst speci¢c
isoenzyme inhibitor used for clinical intervention. Rapid phar-
macologic advancement in this ¢eld and design for other speci¢c
potent antagonists foresees a better control or even chemopreven-
tion of acne, hirsutism, and androgenetic alopecia in the near
future.
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